Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.57 |
| ▸ | HPGD | P15428 | 3/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.57 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.47 |
| ▸ | BRD4 | O60885 | 1/20 | 0.46 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.39 |
| ▸ | CASP1 | P29466 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.38 |
| ▸ | HTR1A | P08908 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7891113 | 0.95 | HPGD (0.53) | MAPTALDH1A1HPGDKDM4EPDE7A | |
| SCHEMBL7189836 | 0.88 | PDE7A (0.60) | MAPTALDH1A1HPGDKDM4EPDE7A | |
| SCHEMBL31457287 | 0.88 | PDE7A (0.60) | MAPTALDH1A1HPGDKDM4EPDE7A | |
| SCHEMBL7194725 | 0.87 | PDE7A (0.47) | MAPTALDH1A1HPGDKDM4EPDE7A | |
| SCHEMBL7189506 | 0.83 | ALDH1A1 (0.56) | MAPTALDH1A1HPGDKDM4EPDE7A | |
| SCHEMBL29083004 | 0.82 | HPGD (0.62) | MAPTALDH1A1HPGDKDM4EPDE7A | |
| SCHEMBL7674839 | 0.80 | HTR1A (0.50) | MAPTALDH1A1HPGDKDM4ECYP3A4 | |
| SCHEMBL9631752 | 0.80 | ALDH1A1 (0.61) | MAPTALDH1A1HPGDKDM4EPDE7A | |
| SCHEMBL12795608 | 0.80 | MAOA (0.44) | MAPTALDH1A1HPGDKDM4EPDE7A | |
| SCHEMBL7184598 | 0.78 | PDE7A (0.44) | MAPTALDH1A1HPGDKDM4EPDE7A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250214948-A1 | TRIAZINE DERIVATIVES FOR TREATING DISEASES RELATING TO NEUROTROPHINS | AlzeCure Pharma AB (SE) | 2025-07-03 | — | — | US | disclosed |
| CN-111819172-B | Triazine derivatives for the treatment of neurotrophin related diseases | 阿泽克制药公司 | 2024-02-06 | — | — | CN | disclosed |
| EP-3759088-B1 | TRIAZINE DERIVATIVES FOR TREATING DISEASES RELATING TO NEUROTROPHINS | AlzeCure Pharma AB (SE) | 2023-01-25 | — | — | EP | disclosed |
| CN-113264856-B | Sulfonium salt, photoacid generator, and photosensitive composition | 东京应化工业株式会社 | 2022-11-22 | — | — | CN | disclosed |
| US-20220306589-A1 | TRIAZINE DERIVATIVES FOR TREATING DISEASES RELATING TO NEUROTROPHINS | AlzeCure Pharma AB (SE) | 2022-09-29 | — | — | US | disclosed |
| US-11352332-B2 | Triazine derivatives for treating diseases relating to neurotrophins | AlzeCure Pharma AB (SE) | 2022-06-07 | — | — | US | disclosed |
| CN-107074759-B | Sulfonium salt, photoacid generator, and photosensitive composition | 东京应化工业株式会社 | 2021-12-14 | — | — | CN | disclosed |
| CN-113264856-A | Sulfonium salt, photoacid generator, and photosensitive composition | 东京应化工业株式会社 | 2021-08-17 | — | — | CN | disclosed |
| EP-3759088-A1 | TRIAZINE DERIVATIVES FOR TREATING DISEASES RELATING TO NEUROTROPHINS | Alzecure Pharma AB (SE) | 2021-01-06 | — | — | EP | disclosed |
| US-20200399230-A1 | TRIAZINE DERIVATIVES FOR TREATING DISEASES RELATING TO NEUROTROPHINS | AlzeCure Pharma AB (SE) | 2020-12-24 | — | — | US | disclosed |
| EP-2948440-B1 | ANTIVIRAL TRIAZOLE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2017-04-12 | — | — | EP | disclosed |
| EP-1147093-B1 | SUBSTITUTED BICYCLIC DERIVATIVES USEFUL AS ANTICANCER AGENTS | PFIZER PROD INC (US) | 2007-04-11 | — | — | EP | disclosed |
| US-20030186995-A1 | Substituted bicyclic derivatives useful as anticancer agents | PFIZER INC. | 2003-10-02 | — | — | US | disclosed |
| CN-1122037-C | Thieno [2, 3-d ] pyrimidinediones, preparation method and use thereof, and pharmaceutical compositions containing the same | ASTRA PHARMA PROD (GB) | 2003-09-24 | — | — | CN | disclosed |
| US-6541481-B2 | A quinazoline compound | PFIZER INC | 2003-04-01 | — | — | US | disclosed |
| US-20010034351-A1 | Substituted bicyclic derivatives useful as anticancer agents | KATH JOHN CHARLES (US) | 2001-10-25 | — | — | US | disclosed |
| EP-1147093-A1 | SUBSTITUTED BICYCLIC DERIVATIVES USEFUL AS ANTICANCER AGENTS | Pfizer Products Inc. (US) | 2001-10-24 | — | — | EP | disclosed |
| US-6284764-B1 | ANTIPROLIFERATIVE AGENT | PFIZER INC. | 2001-09-04 | — | — | US | disclosed |
| CN-1264382-A | Novel compounds | ASTRA PHARMA PROD (GB) | 2000-08-23 | — | — | CN | disclosed |
| WO-2000044728-A1 | SUBSTITUTED BICYCLIC DERIVATIVES USEFUL AS ANTICANCER AGENTS | PFIZER PRODUCTS INC. (US) | 2000-08-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030186995-A1 | Substituted bicyclic derivatives useful as anticancer agents | CCNA1, MCL1, RCC1 | MAPT 4418/4885ALDH1A1 393/4885HPGD 2049/4885 |
| US-20220306589-A1 | TRIAZINE DERIVATIVES FOR TREATING DISEASES RELATING TO NEUROTROPHINS | NTRK2, BDNF, NGF | MAPT 89/4885ALDH1A1 2560/4885HPGD 1200/4885 |
| US-20250214948-A1 | TRIAZINE DERIVATIVES FOR TREATING DISEASES RELATING TO NEUROTROPHINS | NTRK2, BDNF, NGF | MAPT 89/4885ALDH1A1 2560/4885HPGD 1200/4885 |
| US-11352332-B2 | Triazine derivatives for treating diseases relating to neurotrophins | NTRK2, BDNF, NGF | MAPT 79/4885ALDH1A1 2164/4885HPGD 1087/4885 |
| US-20010034351-A1 | Substituted bicyclic derivatives useful as anticancer agents | CCNA1, MCL1, RCC1 | MAPT 4418/4885ALDH1A1 393/4885HPGD 2049/4885 |
| US-20200399230-A1 | TRIAZINE DERIVATIVES FOR TREATING DISEASES RELATING TO NEUROTROPHINS | NTRK2, BDNF, NGF | MAPT 79/4885ALDH1A1 2164/4885HPGD 1087/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.